Related Experiment Video

Updated: May 12, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.0K

Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma

Jules Higué1, Gaetan Basile2, Titouan Cazaubiel2

  • 1CHU de Tolouse, IUCT-Oncopole, Hematology Department, Toulouse 31059, France.

Clinical Lymphoma, Myeloma & Leukemia
|May 9, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.2K

Related Experiment Videos

Last Updated: May 12, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.0K
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

Articles linked to this work by shared authors, journal, and citation graph.

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.

Clinical lymphoma, myeloma & leukemia·2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Leukemia·2026

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

Blood·2026

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study.

Clinical lymphoma, myeloma & leukemia·2026

Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience".

Haematologica·2026

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy.

Clinical lymphoma, myeloma & leukemia·2026

Acute Leukemia During the First Six Months of Life: A Population-Based Analysis of Survival by Leukemia Type.

Clinical lymphoma, myeloma & leukemia·2026

Noninterchangeability of Serum-Free Light Chain Assays at IMWG Thresholds: Analysis of 2117 Paired Samples.

Clinical lymphoma, myeloma & leukemia·2026

The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities.

Clinical lymphoma, myeloma & leukemia·2026

Progression of Disease Within 24 Months (POD24) is an Independent Prognostic Factor for Survival in Waldenström Macroglobulinemia.

Clinical lymphoma, myeloma & leukemia·2026

Identification of the Characteristics and Prognostic Impact of t(3;5)(q25;q35)/NPM1::MLF1 Fusion Genes and NPM1 Mutations in Acute Myeloid Leukemia Patients.

Clinical lymphoma, myeloma & leukemia·2026

Treatment with CFTR modulators and subsequent remission of AA amyloidosis.

Clinical kidney journal·2026

Correction: Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab®.

Frontiers in neuroscience·2026

Comparison of Peg-INF plus TDF versus TDF Monotherapy in Indeterminate-phase Chronic Hepatitis B Patients with High HBsAg levels, HBeAg-negative status, and Normal ALT Levels.

Journal of clinical and translational hepatology·2026

Novel and Emerging Therapies for Childhood-Onset Movement Disorders.

Movement disorders : official journal of the Movement Disorder Society·2026

Implementation of soluble CD38 in blood crossmatching for patients on anti-CD38 therapy: A single-center experience.

Transfusion·2026

FAP+ pericyte-like cells promote monocyte differentiation into tumor-associated macrophages in glioblastoma.

Experimental & molecular medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us